ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Next earnings Aug 5, 2026 · consensus $-1.33 EPS, $56.0M rev
Last earnings -1.5% on 2026-05-07
$78.89
▼ -0.48%$78.89▲ +408.64%
over 1Y
L $14.71EODHDH $82.00
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.5%
1W-3.8%
1M-0.1%
3M+36.5%
YTD+16.4%
1Y+408.6%
Hold
Conviction
Horizon
Long (>12mo)
Street · 20 analysts
Buy
RNAi biotech de-risked by big-pharma deals — now cash-flow positive, but value still rides on unproven clinical pipelines.
Revenue $829M · FY2025
Arrowhead Pharmaceuticals has transformed its financial profile through major partnerships. FY2025 revenue jumped to $829M (from just $3.55M in FY2024), driven by upfront and milestone payments, and the company swung to positive operating income of $98.3M and operating cash flow of $180M — a sharp reversal from the -$463M operating cash burn in FY2024. Net income was essentially breakeven at -$1.63M. The MD&A details the catalysts: a Sarepta collaboration delivering a $500M upfront plus $100M and $200M DM1 milestones, and an October 2025 Novartis deal with a $200M upfront. These validate Arrowhead's RNAi platform with deep-pocketed partners.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $138M | $243M | $241M | $3.55M | $829M |
| Gross profit | — | — | — | — | — |
| Operating income | -$149M | -$179M | -$205M | -$601M | $98.3M |
| Net income | -$141M | -$176M | -$205M | -$599M | -$1.63M |
| Diluted EPS | -$1.36 | -$1.67 | -$1.92 | -$5.00 | -$0.01 |
| Net margin | -101.9% | -72.4% | -85.3% | -16882.4% | -0.2% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$10.5B
EV / EBITDA87.0
EV / Sales12.6
EV / FCF66.8
P / FCF68.3
PEG (trailing)—
Earnings yield-0.0%
FCF yield1.5%
Quality & risk
ROIC (est.)16.7%
Free cash flow$157M
Total debt—
Net cash$227M
Piotroski F-Score4/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+9.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-152026-06-17open ↗3Period ending 2026-06-152026-06-17open ↗8-KPeriod ending 2026-06-122026-06-16open ↗144/AFiling2026-05-19open ↗144/AFiling2026-05-19open ↗144/AFiling2026-05-19open ↗4Period ending 2026-05-122026-05-14open ↗144Filing2026-05-12open ↗S-8Filing2026-05-07open ↗10-QPeriod ending 2026-03-312026-05-07open ↗8-KPeriod ending 2026-05-072026-05-07open ↗SCHEDULE 13GFiling2026-05-06open ↗
Frequently asked
- Is ARROWHEAD PHARMACEUTICALS, INC. (ARWR) a buy?
- ARWR currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. RNAi biotech de-risked by big-pharma deals — now cash-flow positive, but value still rides on unproven clinical pipelines.
- What is ARROWHEAD PHARMACEUTICALS, INC.'s quality score?
- ARWR scores 55.11764705882352/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000879407, latest 10-Q filed 2026-05-07) · EODHD · analysis by claude-code · as of 6/21/2026, 8:48:14 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.